The Immunotherapy of Cancer (ITOC) Forum addresses regulatory issues, hosts workshops and provides education on immunotherapy. It was initiated and run by the CDDF with great success until 2019 and now continues under new management: Wiener Medizinische Akademie GmbH.
The annual conference, the largest immunotherapy meeting in Europe, includes plenary symposium, poster sessions, satellite symposium and an exhibition. The meeting is accredited by the European Council for Continuing Medical Education (EACCME). Find out more about the next conference on http://itoc-conference.eu/
The ITOC Education workshop on cancer immunotherapy, presented by leading faculty in the field, is designed for clinical oncologists, clinical scientists from industry, regulatory scientists, nurses, patient advocates, students and any health professionals involved in treating cancer patients with immunotherapy.
The course provides a greater understanding of cancer immunotherapies, their therapeutic effectiveness and the appropriate selection and management of cancer patients. This will be a one-day programme hosted throughout the year. Find out more and register for the course at http://itoc-conference.eu/itoc-education
Forum workshops on immunotherapies:
- the EMA-CDDF Joint Meeting on the ‘Challenges for the Approval of Anti-Cancer Immunotherapeutic Drugs’ (London, UK – 4 & 5 February 2016)
- the CDDF workshop on ‘Immuno Biomarker Development in the Peripheral Blood’ (Vienna, Austria – 7 & 8 December 2015)